Impact of vitamin D supplementation in the prognosis of patients with SARS-CoV2 pneumonia admitted to the intensive care unit - a randomized controlled trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Their objectives were to evaluate the impact of cholecalciferol supplementation in critical care patients with severe SARS-CoV-2 pneumonia in regards to prognosis, evolution of organ failure and need for organ support.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

A nonblinded controlled trial was conducted in patients with severe SARS-CoV-2 pneumonia admitted to the ICU.

Patients were randomized by block of two, into three groups (no cholecalciferol, 500MU cholecalciferol arm, 2MU/day cholecalciferol during ICU stay and remaining hospitalization).

How the Study Was Run

The design is described as randomized.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Serum 25-hydroxyvitamin D levels were measured and correlated with organ failure indicators (based on SOFA), ICU length of stay, need for organ support, days on mechanical ventilation and ICU, intra-hospital and 60 day mortality.

What Was Measured

Topics PubMed links to this paper include COVID-19, Intensive Care Units, Prognosis, SARS-CoV-2, Vitamin D, Dietary Supplements and Cholecalciferol.

The authors tagged it with the keywords COVID 19, SARS-CoV-2 pneumonia, critical care patients and polyvalent intensive care unit.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Frontiers in immunology), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.